CSPC Pharmaceutical Group Limited (HKG: 1093) announced that top‑line analysis data have been obtained from its Phase III clinical trial evaluating the triple combination therapy of prusogliptin, dapagliflozin, and metformin in patients with type 2 diabetes (T2D). After 24 weeks of treatment, the triple combination demonstrated significantly superior HbA1c reduction from baseline versus both dual‑therapy comparators, along with a favorable safety profile.
Clinical Milestone
| Item | Detail |
|---|---|
| Sponsor | CSPC Pharmaceutical Group Limited (HKG: 1093) |
| Readout Type | Top‑line analysis, Phase III trial |
| Regimen | Prusogliptin + dapagliflozin + metformin triple fixed combination |
| Indication | Type 2 diabetes |
| Treatment Duration | 24 weeks |
| Headline Result | HbA1c reduction from baseline significantly superior to dapagliflozin + metformin or prusogliptin + metformin dual therapy |
| Safety | Overall AE incidence comparable to dual‑therapy regimens; no increase in safety risks |
| Next Steps | Full data set and NDA submission plans not disclosed |
Drug Profile & Mechanism of Action
The triple combination addresses multiple pathological defects of type 2 diabetes through complementary mechanisms:
- Prusogliptin (DPP‑4 Inhibitor): A dipeptidyl peptidase‑IV (DPP‑4) inhibitor that raises endogenous active glucagon‑like peptide‑1 (GLP‑1) levels, thereby increasing insulin secretion in a glucose‑dependent manner and inhibiting glucagon secretion to improve hyperglycemia.
- Dapagliflozin (SGLT2 Inhibitor): A sodium‑glucose cotransporter‑2 inhibitor (SGLT2i) that lowers blood glucose by inhibiting renal glucose reabsorption and promoting urinary glucose excretion – an insulin‑independent mechanism.
- Metformin (Biguanide Backbone): Reduces hepatic glucose production, inhibits intestinal glucose absorption, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
- Combined Clinical Advantages: Beyond enhanced glycemic control, the regimen maintains a low risk of hypoglycemia and offers blood pressure and body weight reduction, pancreatic β‑cell protection, and cardio‑renal benefits.
Clinical Evidence – Phase III Triple Combination Trial
| Endpoint | Result (Triple Therapy) | Comparators | Relative Benefit |
|---|---|---|---|
| HbA1c Reduction from Baseline (24 Weeks) | Significantly superior reduction | Dapagliflozin + metformin; prusogliptin + metformin | Superior efficacy vs. both dual‑therapy arms |
| Overall Adverse Event Incidence | Comparable to dual‑therapy regimens | Both dual‑therapy arms | No increase in safety risks |
| Hypoglycemia Risk | Low, consistent with mechanism profile | – | Favorable tolerability |
| Quantitative Values (HbA1c Δ, AE rates, N) | Not disclosed | – | Top‑line summary only |
The Phase III trial compared the DPP‑4 inhibitor / SGLT2 inhibitor / biguanide triple combination against two active dual‑therapy regimens over 24 weeks. The top‑line analysis confirmed that adding a third mechanistically distinct agent delivered incremental glycemic benefit without a safety penalty – trial size, site count, and exact HbA1c deltas were not disclosed in the announcement.
Market Impact & Outlook
- China T2D Landscape: With one of the world’s largest diabetic populations and intensifying competition in oral antidiabetics, a differentiated single‑regimen triple combination offers CSPC a compelling positioning in both intensification therapy and treatment simplification.
- Mechanistic Rationale: Combining an incretin pathway agent (DPP‑4i), a glucose‑excretion agent (SGLT2i), and metformin covers complementary pathophysiology – aligning with guideline trends favoring multi‑target combination therapy and cardio‑renal protection.
- Pipeline Momentum: Positive top‑line Phase III data move the asset a decisive step closer to registration filing; full data disclosure and NDA timing will be the next catalysts.
- Franchise Synergy: The readout reinforces CSPC’s expanding metabolic disease portfolio and its capability to develop complex fixed‑dose combination products end‑to‑end.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding clinical trial results, regulatory submissions, and commercial expectations for the prusogliptin/dapagliflozin/metformin triple combination. Top‑line data are preliminary and subject to final analysis and regulatory review; actual outcomes may differ materially due to risks including full data verification, approval timelines, and competitive dynamics in the diabetes market.-Fineline Info & Tech
